UK Health Tech Company Zedsen Closes $12M Series B, and Expands Executive Team with New Appointment of Dr. Caroline Hargrove as CTO
LONDON, April 6, 2021 /PRNewswire/
Zedsen, a UK health tech company with a revolutionary non-invasive technology that helps consumers understand their health based on data coming from their bloodstream, today announced a $12 million Series B investment at a $110 million valuation, while also appointing Dr. Caroline Hargrove, former CTO of Babylon Health, as Chief Technology Officer.
The investors include: Joseph R. Grano, former Chairman and CEO of UBS Financial Services Inc; Nasser Kazeminy, Investor, Founder of NJK Holding and Chairman of the Ellis Island Honor Society (EIHS); Tony Rice, Former CEO of Cable and Wireless; Bonnie Mcalveen Hunter, Chairperson of the Red Cross; and Jim Harpel, Investor at Palm Beach Capital.
The technology could replace more inconvenient blood glucose sensors
A UK technology start-up that uses electrical fields to read blood sugar levels has been valued at $110m (£80m) by US investors as it plans to start selling a wearable device to consumers next year.
London-based Zedsen said it had secured $12m in funding from a group of high net-worth investors including Nasser Kazeminy, a multimillionaire businessman, and Robert Priddy, a low-cost-airline mogul.
The company, which is chaired by the former BAE Systems President Sir Charles Masefield, has also poached Caroline Hargrove, the chief technology officer of British health-tech company Babylon.
Application for Admission Application has been made to the London Stock Exchange for the Placing Shares, the Bosch and Director Subscription Shares, and the Retail Shares to be admitted to trading on AIM. Admission is expected to take place, and dealings on AIM are expected to commence, at 8.00 a.m. on 22 March 2021 (or such later time and/or date as may be agreed between the Company and Berenberg and Investec, being no later than 8.00 a.m. on 31 March 2021). No temporary document of title will be issued. Separate Application to the London Stock Exchange will be made for the Weichai Subscription Shares to be admitted to trading on AIM. Subject to completion of the Weichai Subscripton Agreement, admission of the Weichai Subscription Shares to trading on AIM is expected to take place, and dealings on AIM are expected to commence, by 8.00 a.m. on
About Ceres Power Ceres Power ( http://www.cerespower.com ) is a world-leading developer of low cost, next generation solid oxide fuel cell ( SOFC ) technology. Its asset-light licensing model has seen it establish partnerships with some of the world s largest engineering and technology companies, such as Weichai in China, Bosch in Germany, Miura in Japan, and Doosan in South Korea, to develop systems and products that address climate change and air quality challenges for transportation, industry, data centres and everyday living. Ceres Power is listed on the AIM market of the London Stock Exchange ( LSE ) (AIM: CWR) and is classified by the LSE Green Economy Mark, which recognises listed companies that derive more than 50% of their activity from the green economy.